Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform
Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.
Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment
Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.
Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.
Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.